JP2021501318A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501318A5 JP2021501318A5 JP2020523389A JP2020523389A JP2021501318A5 JP 2021501318 A5 JP2021501318 A5 JP 2021501318A5 JP 2020523389 A JP2020523389 A JP 2020523389A JP 2020523389 A JP2020523389 A JP 2020523389A JP 2021501318 A5 JP2021501318 A5 JP 2021501318A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- virus
- disease
- markers
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 186
- 238000000034 method Methods 0.000 claims description 128
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 84
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 84
- 201000010099 disease Diseases 0.000 claims description 67
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 67
- 239000000523 sample Substances 0.000 claims description 60
- 102100024263 CD160 antigen Human genes 0.000 claims description 54
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims description 54
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 54
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 54
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims description 45
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims description 45
- 101100445364 Mus musculus Eomes gene Proteins 0.000 claims description 41
- 101100445365 Xenopus laevis eomes gene Proteins 0.000 claims description 41
- 101150063370 Gzmb gene Proteins 0.000 claims description 35
- 101150043363 GZMK gene Proteins 0.000 claims description 34
- 239000003550 marker Substances 0.000 claims description 32
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 31
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 31
- 241000700605 Viruses Species 0.000 claims description 27
- 230000009385 viral infection Effects 0.000 claims description 24
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 22
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 22
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 22
- 208000036142 Viral infection Diseases 0.000 claims description 22
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 claims description 21
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 claims description 21
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 claims description 19
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 claims description 19
- 102000004503 Perforin Human genes 0.000 claims description 19
- 108010056995 Perforin Proteins 0.000 claims description 19
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 claims description 19
- 210000004027 cell Anatomy 0.000 claims description 19
- 229930192851 perforin Natural products 0.000 claims description 19
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 18
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 18
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 18
- 241000701161 unidentified adenovirus Species 0.000 claims description 18
- 101000713602 Homo sapiens T-box transcription factor TBX21 Proteins 0.000 claims description 17
- 101000599037 Homo sapiens Zinc finger protein Helios Proteins 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 102100036840 T-box transcription factor TBX21 Human genes 0.000 claims description 17
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 claims description 16
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims description 16
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 claims description 16
- 230000001973 epigenetic effect Effects 0.000 claims description 16
- 102100027207 CD27 antigen Human genes 0.000 claims description 15
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 15
- 101001045751 Homo sapiens Hepatocyte nuclear factor 1-alpha Proteins 0.000 claims description 14
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 claims description 14
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims description 14
- 102100022341 Integrin alpha-E Human genes 0.000 claims description 14
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims description 14
- 238000003753 real-time PCR Methods 0.000 claims description 14
- 210000002966 serum Anatomy 0.000 claims description 14
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 12
- 101150115210 PTGER2 gene Proteins 0.000 claims description 12
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 12
- 108090000246 Histone acetyltransferases Proteins 0.000 claims description 11
- 102000003893 Histone acetyltransferases Human genes 0.000 claims description 11
- 102000017578 LAG3 Human genes 0.000 claims description 11
- 101150030213 Lag3 gene Proteins 0.000 claims description 11
- 108010077544 Chromatin Proteins 0.000 claims description 10
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 10
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 10
- 210000003483 chromatin Anatomy 0.000 claims description 10
- 239000013068 control sample Substances 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 10
- 230000037361 pathway Effects 0.000 claims description 10
- 241001529453 unidentified herpesvirus Species 0.000 claims description 10
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 9
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 230000001684 chronic effect Effects 0.000 claims description 9
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims description 8
- 241000701022 Cytomegalovirus Species 0.000 claims description 8
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims description 8
- 108010002350 Interleukin-2 Proteins 0.000 claims description 8
- 102000000588 Interleukin-2 Human genes 0.000 claims description 8
- 208000006454 hepatitis Diseases 0.000 claims description 8
- 231100000283 hepatitis Toxicity 0.000 claims description 8
- 102100021396 Cell surface glycoprotein CD200 receptor 1 Human genes 0.000 claims description 7
- 101000969553 Homo sapiens Cell surface glycoprotein CD200 receptor 1 Proteins 0.000 claims description 7
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 7
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 7
- 230000001154 acute effect Effects 0.000 claims description 7
- 230000003247 decreasing effect Effects 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 241000712461 unidentified influenza virus Species 0.000 claims description 7
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 6
- 206010003445 Ascites Diseases 0.000 claims description 6
- 102000001398 Granzyme Human genes 0.000 claims description 6
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 6
- 101000648265 Homo sapiens Thymocyte selection-associated high mobility group box protein TOX Proteins 0.000 claims description 6
- 241001505332 Polyomavirus sp. Species 0.000 claims description 6
- 102100028788 Thymocyte selection-associated high mobility group box protein TOX Human genes 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 238000011225 antiretroviral therapy Methods 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- 210000004698 lymphocyte Anatomy 0.000 claims description 6
- 210000003097 mucus Anatomy 0.000 claims description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 210000001519 tissue Anatomy 0.000 claims description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 6
- 241001430294 unidentified retrovirus Species 0.000 claims description 6
- -1 Helios Proteins 0.000 claims description 5
- 208000002151 Pleural effusion Diseases 0.000 claims description 5
- 210000002751 lymph Anatomy 0.000 claims description 5
- 102100038778 Amphiregulin Human genes 0.000 claims description 4
- 108010033760 Amphiregulin Proteins 0.000 claims description 4
- 102000049320 CD36 Human genes 0.000 claims description 4
- 108010045374 CD36 Antigens Proteins 0.000 claims description 4
- 108091033409 CRISPR Proteins 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims description 4
- 108060005986 Granzyme Proteins 0.000 claims description 4
- 241000711549 Hepacivirus C Species 0.000 claims description 4
- 241000724675 Hepatitis E virus Species 0.000 claims description 4
- 208000037262 Hepatitis delta Diseases 0.000 claims description 4
- 241000724709 Hepatitis delta virus Species 0.000 claims description 4
- 241000709721 Hepatovirus A Species 0.000 claims description 4
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 claims description 4
- 101000971533 Homo sapiens Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 claims description 4
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 claims description 4
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 4
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 4
- 241000829111 Human polyomavirus 1 Species 0.000 claims description 4
- 241000829106 Human polyomavirus 3 Species 0.000 claims description 4
- 241001237553 Human polyomavirus 6 Species 0.000 claims description 4
- 241000629695 Human polyomavirus 9 Species 0.000 claims description 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 4
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 4
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 4
- 102000003814 Interleukin-10 Human genes 0.000 claims description 4
- 108090000174 Interleukin-10 Proteins 0.000 claims description 4
- 102100030703 Interleukin-22 Human genes 0.000 claims description 4
- 241000701460 JC polyomavirus Species 0.000 claims description 4
- 102100021457 Killer cell lectin-like receptor subfamily G member 1 Human genes 0.000 claims description 4
- 241000713666 Lentivirus Species 0.000 claims description 4
- 102100035304 Lymphotactin Human genes 0.000 claims description 4
- 208000032818 Microsatellite Instability Diseases 0.000 claims description 4
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 4
- 208000030852 Parasitic disease Diseases 0.000 claims description 4
- 101100393514 Rattus norvegicus Gzmm gene Proteins 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 4
- 108010074108 interleukin-21 Proteins 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 230000008685 targeting Effects 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 241000224422 Acanthamoeba Species 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 241000726108 Blastocystis Species 0.000 claims description 3
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 claims description 3
- 241000713730 Equine infectious anemia virus Species 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 241000682990 Pegivirus A Species 0.000 claims description 3
- 241000223821 Plasmodium malariae Species 0.000 claims description 3
- 241000533331 Salmonella bongori Species 0.000 claims description 3
- 241001138501 Salmonella enterica Species 0.000 claims description 3
- 241000224527 Trichomonas vaginalis Species 0.000 claims description 3
- 241000607626 Vibrio cholerae Species 0.000 claims description 3
- 244000000013 helminth Species 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 3
- 229940118768 plasmodium malariae Drugs 0.000 claims description 3
- 229940118696 vibrio cholerae Drugs 0.000 claims description 3
- DTTONLKLWRTCAB-UDFURZHRSA-N (1s,3e,5r,7r)-3-[(3,4-dihydroxyphenyl)-hydroxymethylidene]-6,6-dimethyl-5,7-bis(3-methylbut-2-enyl)-1-[(2s)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]bicyclo[3.3.1]nonane-2,4,9-trione Chemical compound O=C([C@@]1(C(C)(C)[C@H](CC=C(C)C)C[C@](C2=O)(C1=O)C[C@H](CC=C(C)C)C(C)=C)CC=C(C)C)\C2=C(\O)C1=CC=C(O)C(O)=C1 DTTONLKLWRTCAB-UDFURZHRSA-N 0.000 claims description 2
- OMKHWTRUYNAGFG-IEBDPFPHSA-N 3-deazaneplanocin a Chemical compound C1=NC=2C(N)=NC=CC=2N1[C@@H]1C=C(CO)[C@@H](O)[C@H]1O OMKHWTRUYNAGFG-IEBDPFPHSA-N 0.000 claims description 2
- FAWSUKOIROHXAP-NPMXOYFQSA-N 4-[(2s,4r)-1-acetyl-4-(4-chloroanilino)-2-methyl-3,4-dihydro-2h-quinolin-6-yl]benzoic acid Chemical compound N([C@@H]1C[C@@H](N(C2=CC=C(C=C21)C=1C=CC(=CC=1)C(O)=O)C(C)=O)C)C1=CC=C(Cl)C=C1 FAWSUKOIROHXAP-NPMXOYFQSA-N 0.000 claims description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 2
- 241001664176 Alpharetrovirus Species 0.000 claims description 2
- 241000934146 Balamuthia mandrillaris Species 0.000 claims description 2
- 241001231757 Betaretrovirus Species 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 2
- 238000010354 CRISPR gene editing Methods 0.000 claims description 2
- 241000589875 Campylobacter jejuni Species 0.000 claims description 2
- 102000019034 Chemokines Human genes 0.000 claims description 2
- 108010012236 Chemokines Proteins 0.000 claims description 2
- 241000193155 Clostridium botulinum Species 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 241000223935 Cryptosporidium Species 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 claims description 2
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 claims description 2
- 241001663879 Deltaretrovirus Species 0.000 claims description 2
- 241000157306 Dientamoeba fragilis Species 0.000 claims description 2
- 206010058314 Dysplasia Diseases 0.000 claims description 2
- 101710201246 Eomesodermin Proteins 0.000 claims description 2
- 102100030751 Eomesodermin homolog Human genes 0.000 claims description 2
- 241001663878 Epsilonretrovirus Species 0.000 claims description 2
- 241001663880 Gammaretrovirus Species 0.000 claims description 2
- QDKLRKZQSOQWJQ-JGWHSXGBSA-N Garcinol Natural products O=C([C@@]1(C(C)(C)[C@@H](CC=C(C)C)C[C@](C=2O)(C1=O)C[C@H](CC=C(C)C)C(C)=C)CC=C(C)C)C=2C(=O)C1=CC=C(O)C(O)=C1 QDKLRKZQSOQWJQ-JGWHSXGBSA-N 0.000 claims description 2
- 241000224467 Giardia intestinalis Species 0.000 claims description 2
- 108050003624 Granzyme M Proteins 0.000 claims description 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 2
- 241000700721 Hepatitis B virus Species 0.000 claims description 2
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 claims description 2
- 102100022846 Histone acetyltransferase KAT2B Human genes 0.000 claims description 2
- 102100022537 Histone deacetylase 6 Human genes 0.000 claims description 2
- 108010033040 Histones Proteins 0.000 claims description 2
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims description 2
- 101001047006 Homo sapiens Histone acetyltransferase KAT2B Proteins 0.000 claims description 2
- 101000899330 Homo sapiens Histone deacetylase 6 Proteins 0.000 claims description 2
- 101001117519 Homo sapiens Prostaglandin E2 receptor EP2 subtype Proteins 0.000 claims description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 2
- 241000701041 Human betaherpesvirus 7 Species 0.000 claims description 2
- 241001502974 Human gammaherpesvirus 8 Species 0.000 claims description 2
- 241000701027 Human herpesvirus 6 Species 0.000 claims description 2
- 241001500351 Influenzavirus A Species 0.000 claims description 2
- 241001500350 Influenzavirus B Species 0.000 claims description 2
- 241001500343 Influenzavirus C Species 0.000 claims description 2
- 241000401052 Influenzavirus D Species 0.000 claims description 2
- 241000222722 Leishmania <genus> Species 0.000 claims description 2
- 241000186779 Listeria monocytogenes Species 0.000 claims description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 2
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 claims description 2
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 claims description 2
- QGZYDVAGYRLSKP-UHFFFAOYSA-N N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)-5-pyrimidinecarboxamide Chemical compound N1=CC(C(=O)NCCCCCCC(=O)NO)=CN=C1N(C=1C=CC=CC=1)C1=CC=CC=C1 QGZYDVAGYRLSKP-UHFFFAOYSA-N 0.000 claims description 2
- 241000224438 Naegleria fowleri Species 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 241000223960 Plasmodium falciparum Species 0.000 claims description 2
- 241000223801 Plasmodium knowlesi Species 0.000 claims description 2
- 241001505293 Plasmodium ovale Species 0.000 claims description 2
- 241000223810 Plasmodium vivax Species 0.000 claims description 2
- 102100024448 Prostaglandin E2 receptor EP2 subtype Human genes 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 241000713675 Spumavirus Species 0.000 claims description 2
- 241000191967 Staphylococcus aureus Species 0.000 claims description 2
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 2
- 241000223997 Toxoplasma gondii Species 0.000 claims description 2
- 241001654786 Trichodysplasia spinulosa-associated polyomavirus Species 0.000 claims description 2
- 241000223104 Trypanosoma Species 0.000 claims description 2
- 241000223109 Trypanosoma cruzi Species 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 230000003321 amplification Effects 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 229940109262 curcumin Drugs 0.000 claims description 2
- 235000012754 curcumin Nutrition 0.000 claims description 2
- 239000004148 curcumin Substances 0.000 claims description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 2
- 230000003511 endothelial effect Effects 0.000 claims description 2
- LMFLOMBYUXRHIL-UHFFFAOYSA-N garcifuran-A Natural products COC1=C(O)C(OC)=CC(C=2C(=C3C=COC3=CC=2)O)=C1 LMFLOMBYUXRHIL-UHFFFAOYSA-N 0.000 claims description 2
- 229940085435 giardia lamblia Drugs 0.000 claims description 2
- GRBCIRZXESZBGJ-UHFFFAOYSA-N guttiferone F Natural products CC(=CCCC(C(=C)C)C12CC(CC=C(C)C)C(C)(C)C(CC=C(C)C)(C(=O)C(=C1O)C(=O)c3ccc(O)c(O)c3)C2=O)C GRBCIRZXESZBGJ-UHFFFAOYSA-N 0.000 claims description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims description 2
- 208000021039 metastatic melanoma Diseases 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 230000011987 methylation Effects 0.000 claims description 2
- 238000007069 methylation reaction Methods 0.000 claims description 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 2
- 230000002250 progressing effect Effects 0.000 claims description 2
- 229940121649 protein inhibitor Drugs 0.000 claims description 2
- 239000012268 protein inhibitor Substances 0.000 claims description 2
- 238000012163 sequencing technique Methods 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 210000001635 urinary tract Anatomy 0.000 claims description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims description 2
- 229960000237 vorinostat Drugs 0.000 claims description 2
- 241000224016 Plasmodium Species 0.000 claims 6
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 2
- 241000224432 Entamoeba histolytica Species 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 229940007078 entamoeba histolytica Drugs 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 210000004880 lymph fluid Anatomy 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 210000004910 pleural fluid Anatomy 0.000 claims 1
- 230000009467 reduction Effects 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 241000224489 Amoeba Species 0.000 description 1
- 241000242722 Cestoda Species 0.000 description 1
- 108010034145 Helminth Proteins Proteins 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 241000869417 Trematodes Species 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 238000012015 optical character recognition Methods 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762578193P | 2017-10-27 | 2017-10-27 | |
| US201762578212P | 2017-10-27 | 2017-10-27 | |
| US62/578,212 | 2017-10-27 | ||
| US62/578,193 | 2017-10-27 | ||
| US201862660754P | 2018-04-20 | 2018-04-20 | |
| US62/660,754 | 2018-04-20 | ||
| US201862661467P | 2018-04-23 | 2018-04-23 | |
| US62/661,467 | 2018-04-23 | ||
| PCT/US2018/057850 WO2019084493A1 (en) | 2017-10-27 | 2018-10-26 | METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SUSPECTED T CELLS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021501318A JP2021501318A (ja) | 2021-01-14 |
| JP2021501318A5 true JP2021501318A5 (enExample) | 2021-12-09 |
| JP7430136B2 JP7430136B2 (ja) | 2024-02-09 |
Family
ID=66246753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020523389A Active JP7430136B2 (ja) | 2017-10-27 | 2018-10-26 | 疲弊したｔ細胞に関連する疾患を治療するための方法および組成物 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US11906511B2 (enExample) |
| EP (1) | EP3701041A4 (enExample) |
| JP (1) | JP7430136B2 (enExample) |
| WO (1) | WO2019084493A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USD1083956S1 (en) * | 2018-12-10 | 2025-07-15 | Icahn School Of Medicine At Mount Sinai | Display screen with a graphical user interface |
| WO2020246846A1 (ko) * | 2019-06-05 | 2020-12-10 | 연세대학교 산학협력단 | Tox에 기초한 면역 항암 요법에 대한 치료 반응 예측 방법 |
| WO2021006316A1 (ja) * | 2019-07-10 | 2021-01-14 | 国立研究開発法人国立がん研究センター | がん細胞を特異的に攻撃しているｔ細胞を同定するための特異的マーカー |
| EP4055180A4 (en) * | 2019-11-05 | 2023-12-06 | Cofactor Genomics, Inc. | METHODS AND SYSTEMS FOR PROCESSING COMPLEX DATA SETS USING ARTIFICIAL INTELLIGENCE AND DECONVOLUTION |
| CN111154835A (zh) * | 2020-01-19 | 2020-05-15 | 广州基迪奥生物科技有限公司 | 一种ATAC-seq测序文库的构建方法 |
| EP4133059A4 (en) * | 2020-04-07 | 2024-10-02 | University Health Network | COMPOSITIONS AND METHODS FOR INCREASING CD8+ T CELL ACTIVATION AND CYTOLYTIC ACTIVITY BY DISRUPTION OF THE SAGA (SPT-ADA-GCN5-ACETYLTRANSFERASE) COMPLEX |
| CN115768879A (zh) | 2020-04-28 | 2023-03-07 | 莱尔免疫制药公司 | 用于培养细胞的方法 |
| CN111748627A (zh) * | 2020-07-02 | 2020-10-09 | 北京化工大学 | 膀胱癌耗竭型t细胞亚群、其特征基因及其应用 |
| CA3193687A1 (en) * | 2020-09-23 | 2022-03-31 | The Trustees Of Columbia University | Metabolic augmentation to promote and enhance immune response by tcf1+ t cell repopulation |
| CN112501292B (zh) * | 2020-11-09 | 2022-12-02 | 中国人民解放军海军军医大学 | cFAM210A在制备肝癌诊断或术后预测试剂盒以及药物中的应用 |
| EP4301773A4 (en) * | 2021-03-03 | 2025-06-25 | The Board of Trustees of the Leland Stanford Junior University | POLYPEPTIDE CONSTRUCTS WITH NOVEL BINDING AFFINITY AND USES THEREOF |
| WO2023023269A1 (en) * | 2021-08-20 | 2023-02-23 | The Board Of Trustees Of The Leland Stanford Junior University | Identification of pathogenic immune cell subsets in checkpoint inhibitor-induced myocarditis |
| WO2023034530A1 (en) * | 2021-09-02 | 2023-03-09 | Teon Therapeutics, Inc. | Methods of improving growth and function of immune cells |
| WO2023060071A1 (en) * | 2021-10-04 | 2023-04-13 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Dna methylation signatures for predicting response to immunotherapy |
| CN118251487A (zh) * | 2021-10-26 | 2024-06-25 | 巴黎-萨克雷大学 | 源自高功能性自体干细胞的t细胞免疫疗法 |
| JP2023064788A (ja) * | 2021-10-27 | 2023-05-12 | 国立大学法人京都大学 | Ｔ細胞の評価方法及びｔ細胞評価用の組成物 |
| CN115040538A (zh) * | 2022-05-23 | 2022-09-13 | 重庆医科大学 | 人cxcr5＋cd8＋t细胞在制备治疗慢性乙型肝炎的药物中的应用 |
| CN114752628B (zh) * | 2022-05-30 | 2023-06-30 | 四川大学华西医院 | C57bl/6小鼠多发性骨髓瘤模型的构建方法及应用 |
| CN115029429B (zh) * | 2022-06-02 | 2022-11-22 | 中国人民解放军总医院第五医学中心 | 炎症相关蛋白联合在预测art治疗敏感性中的应用 |
| CN115040663B (zh) * | 2022-06-15 | 2023-12-12 | 上海交通大学医学院附属仁济医院 | 溶质载体家族38成员2在制备多发性骨髓瘤治疗药物中的应用 |
| CN115058504B (zh) * | 2022-07-14 | 2025-07-04 | 广州医科大学 | 膀胱癌th17 cd4+t细胞亚群及其特征基因与应用 |
| WO2024074713A1 (en) * | 2022-10-07 | 2024-04-11 | Institut National de la Santé et de la Recherche Médicale | Method to generate improving car-t cells |
| WO2024097677A1 (en) * | 2022-11-01 | 2024-05-10 | BioLegend, Inc. | Analyzing per-cell co-expression of cellular constituents |
| CN119700985A (zh) * | 2023-09-22 | 2025-03-28 | 清华大学 | Bcor和Zc3h12a在预防和治疗慢性感染中的用途 |
| CN117017991A (zh) * | 2023-09-26 | 2023-11-10 | 中山大学附属第三医院 | Hdac6选择性抑制剂在制备慢性乙型病毒性肝炎抗病毒治疗药物中的应用 |
| CN118818055A (zh) * | 2024-06-05 | 2024-10-22 | 复旦大学附属华山医院 | 用于筛选胶质瘤dc疫苗潜在受益人群的试剂盒及应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2212350B1 (en) * | 2007-10-26 | 2013-08-28 | Governing Council of the University of Toronto | Treating chronic viral infection by targetting TIM-3 |
| WO2016061456A2 (en) | 2014-10-17 | 2016-04-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of t-cell exhaustion using cd39 biomarkers and modulators |
| WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
| KR20190080825A (ko) * | 2016-03-21 | 2019-07-08 | 다나-파버 캔서 인스티튜트 인크. | T-세포 기능소실 상태-특이적 유전자 발현 조절인자 및 그 용도 |
-
2018
- 2018-10-26 JP JP2020523389A patent/JP7430136B2/ja active Active
- 2018-10-26 US US16/759,676 patent/US11906511B2/en active Active
- 2018-10-26 WO PCT/US2018/057850 patent/WO2019084493A1/en not_active Ceased
- 2018-10-26 EP EP18870493.6A patent/EP3701041A4/en active Pending
-
2024
- 2024-01-03 US US18/403,429 patent/US20240264151A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021501318A5 (enExample) | ||
| AU2019249422B2 (en) | Methylation markers and targeted methylation probe panels | |
| Bas et al. | Utility of the housekeeping genes 18S rRNA, β‐actin and glyceraldehyde‐3‐phosphate‐dehydrogenase for normalization in real‐time quantitative reverse transcriptase‐polymerase chain reaction analysis of gene expression in human T lymphocytes | |
| Ekiz et al. | MicroRNA-155 coordinates the immunological landscape within murine melanoma and correlates with immunity in human cancers | |
| US10870885B2 (en) | Dendritic cell response gene expression, compositions of matters and methods of use thereof | |
| Wang | The opening of pandora's box: an emerging role of long noncoding RNA in viral infections | |
| US20190263912A1 (en) | Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action | |
| De Simone et al. | CXCR3 identifies human naive CD8+ T cells with enhanced effector differentiation potential | |
| US20190144942A1 (en) | Methods for identifying and modulating immune phenotypes | |
| WO2019079647A2 (en) | IA STATISTICS FOR DEEP LEARNING AND PROBABILISTIC PROGRAMMING, ADVANCED, IN BIOSCIENCES | |
| Davar et al. | Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial | |
| Ghosh et al. | Strong correlation between air-liquid interface cultures and in vivo transcriptomics of nasal brush biopsy | |
| US20230223105A1 (en) | Mitigation of statistical bias in genetic sampling | |
| Guo et al. | Comprehensive analysis of m6A RNA methylation regulators and the immune microenvironment to aid immunotherapy in pancreatic cancer | |
| US20240167933A1 (en) | Flow cytometry immunoprofiling of peripheral blood | |
| Burchill et al. | Single-cell transcriptomic analyses of T cells in chronic HCV-infected patients dominated by DAA-induced interferon signaling changes | |
| KR20190032374A (ko) | 엑소좀-안내 암 치료(exosome-guided treatment of cancer) | |
| Cristalli et al. | Targeting DNA methylation machinery in pediatric solid tumors | |
| WO2005021745A1 (ja) | 肝細胞癌に関連する遺伝子 | |
| US20220136070A1 (en) | Methods and systems for characterizing tumor response to immunotherapy using an immunogenic profile | |
| Zheng et al. | Multi-omics profiling identifies C1QA/B+ macrophages with multiple immune checkpoints associated with esophageal squamous cell carcinoma (ESCC) liver metastasis | |
| CN116287158A (zh) | 一种新抗原鉴定和疗效预测方法 | |
| Hou et al. | Analysis of the transcriptome and immune function of monocytes during IFNα-based therapy in chronic HCV revealed induction of TLR7 responsiveness | |
| Razzuoli et al. | Reverse transcription real‐time PCR for detection of porcine interferon α and β genes | |
| Li et al. | Identification of immunosenescence of unconventional T cells in hepatocellular carcinoma |